Terkko Navigator / Aittokallio, T(ero)* (FIMM)

A relational database to identify differentially expressed genes in the endometrium and endometriosis lesions.

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.

KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia.

Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer.

Prediction of drug combination effects with a minimal set of experiments.

SynergyFinder 2.0: visual analytics of multi-drug combination synergies.

A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer.

Improved detection of differentially represented DNA barcodes for high-throughput clonal phenomics.

Characterizing the Quality of Insight by Interactions: A Case Study.

Breeze: an integrated quality control and data analysis application for high-throughput drug screening.

SynergyFinder: a web application for analyzing drug combination dose-response matrix data.

Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine.

Phosphoproteome and drug response effects mediated by the three Protein Phosphatase 2A inhibitor proteins CIP2A, SET and PME-1.

UBR5 is co-amplified with MYC in breast tumors and encodes an ubiquitin ligase that limits MYC-dependent apoptosis.

SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy.

A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening.

Modelling of killer T-cell and cancer cell subpopulation dynamics under immuno- and chemotherapies.

Genetic and functional implications of an exonic TRIM55 variant in heart failure.

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T cell cytotoxicity.

Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets.

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL.

Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival.

Chemogenomic Analysis of the Druggable Kinome and Its Application to Repositioning and Lead Identification Studies.

Genome-wide off-targets of drugs: risks and opportunities.

Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer.

DNMT Inhibitors Increase Methylation in the Cancer Genome.

Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets.

Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy.

Interactive visual analysis of drug-target interaction networks using Drug Target Profiler, with applications to precision medicine and drug repurposing.

Integrated Analysis of Drug Sensitivity and Selectivity to Predict Synergistic Drug Combinations and Target Coaddictions in Cancer.

Adrenals Contribute to Growth of Castration-Resistant VCaP Prostate Cancer Xenografts.

Drug Target Commons 2.0: a community platform for systematic analysis of drug-target interaction profiles.

Machine learning and feature selection for drug response prediction in precision oncology applications.

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.

Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths.

Drug sensitivity screening and genomic characterization of 45 HPV-negative head and neck carcinoma cell lines for novel biomarkers of drug efficacy.

Learning with multiple pairwise kernels for drug bioactivity prediction.

Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.

ePCR: an R-package for survival and time-to-event prediction in advanced prostate cancer, applied to real-world patient cohorts.

The rocky road to personalized medicine: computational and statistical challenges.

Novel activities of safe-in-human broad-spectrum antiviral agents.

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.

Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.

Patient-customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.

Secreted frizzled-related protein 2 (SFRP2) expression promotes lesion proliferation via canonical WNT signaling and indicates lesion borders in extraovarian endometriosis.

Instability of LDL particles predicts future cardiovascular deaths.

Methods for High-throughput Drug Combination Screening and Synergy Scoring.

Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions.

Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery.

Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.